Goldman Sachs Global Healthcare Conference

Colfax Corporation Chris Hix, EVP & CFO Brady Shirly, EVP & CEO of DJO June 9th, 2021



Forward Looking Statements & Non-GAAP Disclaimer

These materials include "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be characterized by terms such as "believe," "anticipate," "strategy," "targets," "aims," "seeks," "sees" and similar expressions. All statements of historical fact could be deemed forward-looking statements, including, but not limited to, statements reparation; the intended separation of the FabTech and MedTech; businesses; expected 2021 revenue and Adjusted EBITDA for FabTech and MedTech; long-term financial goals for FabTech and MedTech; the timing and method of the separation; the anticipated benefits of the separation; the expected financial and operating performance of, and future opportunities for, each company following the separation. These statements are based on assumptions and assessments made by our management as of the date of this presentation in light of their experience and perception of historical trends, current conditions, expected future developments, strategy, outlook, goals and other factors believed to be appropriate. Forward-looking statements are subject to a number of risks, uncertainties and assumptions that might cause actual results. developments and business decisions to differ materially from those expressed or implied thereby, and are not guarantees of future performance or acual results. These factors include, among other things: the financing and other transaction; including rulings from the Internal Revenue Service; the ability to successfully complete financing and other transaction; and the inancial and operating performance of and the coNUD-19 pandemic on the separation on a timely basis, or at all; our ability to successfully separate the two companies and realize the anticipated benefits of the separation; the ability to successfully separate the two companies and realize the anticipated benefits of the pandemic, and other impacts on our business and ability to execute business continuity plans; and our ability to

The factors identified above are not exhaustive. We operate in a dynamic business environment in which new risks may emerge frequently. Other unknown or unpredictable factors could also cause actual results, developments and business decisions to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements should be construed in the light of such factors. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date made. Additional information regarding these and other factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements is set forth in our public filings with the Securities Exchange Commission (the "SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2020 and our subsequent filings with the SEC. We do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Colfax has provided in this presentation certain financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"). These non-GAAP financial measures include adjusted EBITDA (adjusted EBITDA plus depreciation and other amortization), adjusted EBITDA margin, organic (core) sales growth, and free cash flow. Colfax also provides adjusted EBITDA, adjusted EBITDA margin, organic (core) sales growth and free cash flow on a segment basis.

• Adjusted EBITA represents net income (loss) from continuing operations excluding restructuring and other related charges, acquisition-related amortization and other non-cash charges, European Union Medical Device Regulation ("MDR") and other costs, and strategic transaction costs, as well as income tax expense (benefit) and interest expense, net. Colfax presents adjusted EBITA margin, which is subject to the same adjustments as adjusted EBITA. Further, Colfax presents adjusted EBITA (and adjusted EBITA margin) on a segment basis, where we exclude the impact of strategic transaction costs and acquisition-related amortization and other non-cash charges from segment operating income.

- Adjusted EBITDA represents Adjusted EBITA plus depreciation and other amortization.
- Core or organic sales growth (decline) excludes the impact of acquisitions and foreign exchange rate fluctuations.
- Decremental margin represents the change in Adjusted EBITDA divided by the change in net sales.
- Free cash flow represents cash flow from operating activities less purchases of property, plant and equipment.

These non-GAAP financial measures assist Colfax management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of Colfax. Colfax management also believes that presenting these measures allows investors to view its performance using the same measures that Colfax uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures provided in the appendix to this presentation.

In this presentation, Colfax presents forward-looking non-GAAP measures, such as Adjusted EBITDA, Adjusted EBITDA and Free Cash Flow on a segment basis. Colfax does not provide such outlook on a GAAP basis because changes in the items that Colfax excludes from GAAP to calculate such measures can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of Colfax's routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis.

Re-Shaped Portfolio for Maximum Value Creation

2017-2019 Transformation


- Portfolio changes
- Created outperforming FabTech business

2019-2020 Momentum

- Strengthened talent, accelerated MedTech capabilities
- Invested in innovation and strategic acquisitions

2021 - Future

- Leaders in attractive, growing markets
- Sustainable business models for compounding value creation



\$3B+ Specialty MedTechCo with HSD Growth, Capital Allocation Focused on Growth

\$3B+ FabTech Leader with MSD Growth, Balanced Capital Allocation

2019

Businesses are Ready to be Independent, Publicly-Traded Companies



Strategic Rationale for the Separation is Compelling

- Announced on March 4th the intent for a tax-free separation into two independent, publicly traded companies (completion targeted in the first quarter 2022)
- Creates focused specialty Medical Technologies and Fabrication Technology companies, positioning both to accelerate strategic momentum
- Enables each company to sharpen its strategic focus to capitalize on distinct investment opportunities



Allows each to be valued based on distinct strategic, operational and financial characteristics



Recent equity offering strengthens balance sheet and creates flexibility

Now Is the Right Time to Build on the Momentum in Both Businesses



Two Great Companies, Well-Positioned for Success

Global Fabrication Technology Leader



~\$2.3B Revenue¹ / ~\$.4B Adj. EBITDA¹

- >\$30B market, global GDP + accelerators
- Global leader with scale in all regions
- Strong brands and innovation engine
- Automating industrial workflows

Specialty Medical Technology Innovator

MedTechCo ~\$1.4B Revenue¹ / ~\$.3B Adj. EBITDA¹

- >\$50B market, healthcare growth drivers
- Focused in attractive segments
- Strong brands, innovation building
- Automating clinic workflows

Key Peers							
FabTech Leaders	Ortho Leaders	MedTech MidCaps					
Lincoln Electric	Stryker	Ossur					
ITW - Miller	Zimmer Biomet	Conmed					
	Wright Medical*	Teleflex					


Large, Attractive Markets Great Opportunities for Profitable Growth


* Recently acquired by Stryker

¹ Segment-Level 2021 Estimates



Businesses are Ready for the Separation






Each Business Has The Team and Core Capabilities to Drive Superior Performance



Strengthened Balance Sheet

- Successfully completed equity offering for 16.1 million shares with net proceeds of \$711mm
- Redeemed \$700 million of outstanding senior notes; strengthened balance sheet
- Enables near term flexibility to execute on additional M&A and allows each business to be appropriately capitalized upon separation




Positioning both businesses for strong growth and long-term value creation



Strong Q1 Performance, Improved FY Guidance

As communicated on April 29, 2021

- Raising low-end of full year aEPS guidance to
 \$2.05 \$2.15 (previously \$2.00 2.15)
 - Strong Q1 performance
 - Offsetting ESAB inflationary pressures with price increases; 4%+ higher sales vs. prior guidance
 - Adjusted EBITDA inline with Investor Day ranges
 - ~\$(0.04) net impact from equity issuance and bond redemptions (1c in 2H)
- Q2 aEPS forecast of \$0.48 \$0.53
- Clear line-of-sight to FY FCF of > \$250mm and ~90% conversion




Strong growth projected across both businesses in 2021




Strong MedTech Growth Platform in >\$50B Market

2019 INDUSTRY SALES¹ (\$B)



TOP ORTHO PLAYERS (\$B)²



MedTechCo is Positioned for Share Gain and Expansion


¹Source: based on internal Medtech analysis

² 2019 sales per public filings; MedTechCo 2019 shown pro forma to include periods prior to DJO acquisition on February 22, 2019

³ Acquired by Stryker in 2020



MedTechCo



10

colta

¹ See appendix for non-GAAP reconciliations, 2019 shown pro forma to include periods prior to DJO acquisition on February 22, 2019

² Mix shown reflects business realignment of Bone Growth Stimulation now included within Preventative and Rehabilitation


³ Vitality defined as new product revenue (introduced in last 3 years) as a percentage of total revenue

Fast-Growing Recon Business with Proven Playbook

MedTechCo

RECON SALES & MARKET POSITION¹

\$20B Market




Majority of sales in fast growing Extremities segment

Pioneered U.S. transition from Anatomic to Reverse shoulder

Large global expansion opportunity: 94% US Sales

Well-positioned in faster-growing ASC segment

U.S. RECONSTRUCTIVE CORE SALES GROWTH (CAGR)



PROVEN PLAYBOOK, ABOVE MARKET GROWTH


- Superior clinical outcomes
- Industry leading Key Opinion Leader (KOL) teams
- Unmatched innovation cadence
- Best-in-class medical education platform
- DonJoy brand and contracting power



Market Leader in Prevention & Recovery with Iconic Brands

MedTechCo

P&R SALES & MARKET POSITION¹



MARKET LEADERSHIP

- Returned to market growth levels in 2H 2019 ٠
- Superior clinical outcomes ٠
- Leader in fast growing Sports Medicine segment •
- Strong contract position across all GPOs ٠
- Leader in therapy modalities strengthened by Litecure[™] ٠

TECHNOLOGY LEADERSHIP

Industry-defining products across the Ortho continuum

MotionMD workflow software solution drives 40% of US Clinics

Deep penetration in global markets: 34% ex-US Sales





Aircast®

Chattanooga[®]

ProCare®

¹ Source: based on internal Medtech analysis. ² 2021 sales estimates



Unique Position Across Full Care Continuum

MedTechCo

PREVENTION-

REPAIR ---

RECOVERY



ADVANTAGES

Digital workflow solutions for clinics

Connected medicine solutions for patient journey


• ASC, Bundled Care partner in full episode of care

Leveraging Access and Technology for Strategic Advantage



Accelerated Innovation Driving Core Growth

MedTechCo




Progress and Pipeline to Hold 30%+ Recon Vitality

¹ Vitality defined as new product revenue (introduced in last 3 years) as a percentage of total revenue.



Re-Shaping MedTechCo for Faster Growth




colfax

15

- Specialty MedTech innovator uniquely positioned for significant value creation
- Foundation in attractive Orthopedic market with favorable long term megatrends
- Strong team leading evolving portfolio and accelerating growth
- Clear strategy with exciting pipeline of new products, digital expansions and ASC solutions
- Significant acquisition opportunities in attractive spaces with appealing financial profiles
- Colfax Business System integrated to deliver compounding value creation

MedTechCo



Non-GAAP Reconciliation

	Fabrication Technology														
	Years Ended December 31,														
		2016			2017		2018			2019			2020		
Net sales	\$	1,800.5		\$	1,937.3		\$	2,193.1		\$	2,247.0		\$	1,950.1	
Operating income		163.7	9.1%		208.2	10.7%		220.9	10.1%		279.6	12.4%		224.4	11.5%
Restructuring and other related charges		31.7			16.2			29.1			23.0			21.6	
Segment operating income	\$	195.4	10.9%	\$	224.4	11.6%	\$	249.9	11.4%	\$	302.6	13.5%	\$	246.0	12.6%
Acquisition-related amortization and other non-cash charges ⁽¹⁾	<u> </u>	30.9			31.9			40.0			35.6			36.3	
Adjusted EBITA	\$	226.3	12.6%	\$	256.3	13.2%	\$	290.0	13.2%	\$	338.2	15.1%	\$	282.3	14.5%
Depreciation and other amortization		41.7			40.1			39.9			41.0			38.4	
Adjusted EBITDA	\$	268.0	14.9%	\$	296.4	15.3%	\$	329.9	15.0%	\$	379.2	16.9%	\$	320.7	16.4%

(1) Includes amortization of acquired intangibles and fair value charges on acquired inventory.



Note: Dollars in millions. Some periods may not foot due to rounding.

Non-GAAP Reconciliation

	 Medical Tech \$	nology ⁽¹⁾ %
Net sales for the year ended December 31, 2018	\$ 1,201.9	
Components of change:		
Existing businesses ⁽²⁾	52.3	4.4%
Acquisitions ⁽³⁾	10.7	0.9%
Foreign currency translation ⁽⁴⁾	 (15.4)	-1.3%
	 47.7	4.0%
Net sales for the year ended December 31, 2019	\$ 1,249.6	

(1) Medical Technology prior year Net sales and sales components are based on or derived from Management's internal reports. On the Company's Form 10-K, Medical Technology 2019 Net sales include only sales subsequent to February 22, 2019, the date of the DJO acquisition, and all sales during the year ended December 31, 2019 are included in the Acquisitions line item of the change in sales reconciliation.

(3) Represents the incremental sales from acquisitions.

⁽²⁾ Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price, product mix and volume.

⁽⁴⁾ Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

Non-GAAP Reconciliation

	Medical Technology												
	As Reported			Add: <u>Two Months Ended February 22,</u> 2019 ⁽¹⁾			Pro Forma Year Ended December 31, 2019						
	Year Ended December 31,		Year Ended December 31, 2020										
	2019												
Net sales	\$	1,080.4		\$	169.2		\$	1,249.6		\$	1,120.7		
Operating income (loss)		45.5	4.2%								(1.2)	-0.1%	
Restructuring and other related charges ⁽²⁾		50.7									23.4		
Medical device regulation costs ⁽³⁾		-									6.9		
Segment operating income	\$	96.2	8.9%							\$	29.1	2.6%	
Acquisition-related amortization and other non-cash charges ⁽⁴⁾		102.9									107.6		
Adjusted EBITA	\$	199.0	18.4%							\$	136.7	12.2%	
Depreciation and other amortization		49.0									64.6		
Adjusted EBITDA	\$	248.0	23.0%	\$	30.2	17.9%	\$	278.2	22.3%	\$	201.3	18.0%	

(1) The Net sales and Adjusted EBITDA figures for the two months ended February 22, 2019 are based on or derived from Management's internal reports. The Colfax 2020 Form 10-K only includes prior year Medical Technology segment results subsequent to February 22, 2019, the date of the DJO acquisition.

(3) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017.

(4) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

⁽²⁾ Restructuring and other related charges includes \$6.6 and \$8.5 of expense classified as Cost of sales on the Company's Consolidated Statements of Operations for the years ended December 31, 2020 and December 31, 2019, respectively.